Department of Medicine

Cardiovascular Medicine Faculty

Carl J. Pepine, M.D., M.A.C.C. Eminent Scholar Emeritus Professor of Medicine Division of Cardiovascular Medicine e-mail: pepincj@medicine.ufl.edu 1600 SW Archer Road/Box 100277 Gainesville, FL  32610-0277 352 846 3292/FAX 352 371 0370

Carl J. Pepine, MD, is Eminent Scholar Emeritus and Professor of Medicine, Division of Cardiovascular Medicine at the University of Florida College of Medicine in Gainesville, Florida. He is a graduate of the University of Pittsburgh and the College of Medicine of New Jersey.

Training:

Academic Interests:

Dr. Pepine is an internationally recognized leader in both the clinical and scientific areas of cardiovascular medicine. His major interests focus on the pathophysiology of ischemic heart disease and coronary and systemic vascular hemodynamic mechanisms underlying the disease. He is principal investigator for the UF center for the NHLBI-funded Women’s Ischemia Syndrome Evaluation (WISE) and the UF center for the Cardiovascular Cell Therapy Research Network (CCTRN). He has been or is the PI for many investigator initiated clinical trials. He is past president of the American College of Cardiology (ACC), the professional organization for cardiovascular physicians. He currently serves on the Board of Trustees of the ACC and many committees and task forces and is the founder and overall Project Chair for the Vascular Biology Working Group (VBWG).

Clinical Interests:

Ischemic heart disease, heart disease in women, cardiovascular cell therapy, preventive cardiology, genetic cardiology, clinical trials in cardiovascular disease.

Representative Publications:

• Pepine CJ, Rouleau JL, Annis K, Ducharme A, Ma P, Lenis J, Davies R, Thadani U, Chaitman B, Haber HE, Freedman SB, Pressler ML, Pitt B, QUASAR Study Group. Effects of angiotensin converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. J Am Coll Cardiol 42(12):2049-2059, 2003.
• Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA for the Combination Assessment of Ranolazine in Stable Angina (CARISA) investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial. JAMA 291(3):309-316, 2004.
• Marroquin OC, Kip KE, Kelley DE, Johnson BD, Shaw LJ, Bairey Merz CN, Sharaf BL, Pepine CJ, Sopko G, Reis SE, for the Women’s Ischemia Syndrome Evaluation Investigators. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: A report from the Women’s Ischemia Syndrome Evaluation. Circulation 109(6):714-721, 2004.
• von Mering GO, Arant CB, Wessel TR, McGorray SP, Bairey Merz CN, Sharaf BL, Smith KM, Olson MB, Johnson BD, Sopko G, Handberg E, Pepine CJ, Kerensky RA. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: Results from the National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation 109(6):722-725, 2004.
• Johnson BD, Kip DE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, Pepine CJ, Sharaf B, Bairey Merz CN, Sopko G, Olson MB, Reis SE. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: The National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation 109(6):726-732, 2004.
• Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Juch J, Pepine CJ, Wang W, Nelson JJ, Hebert DA, Wolff AA, MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 43(8):1375-1382, 2004.
• Johnson BD, Shaw LJ, Buchthal SD, Bairey Merz CN, Kim HW, Scott KN, Doyle M, Olson MB, Pepine CJ, den Hollander J, Sharaf B, Rogers WJ, Mankad S, Forder JR, Kelsey SF, Pohost GM. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: Results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation 109(24):2993-2999, 2004.
• Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H, SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial. JAMA 292(1):45-54, 2004.
• Wessel TR, Arant CB, Olson MB, Johnson BD, Reis SE, Sharaf BL, Shaw LJ, Handberg E, Sopko G, Kelsey SF, Pepine CJ, Bairey Merz CN. Relationship of physical fitness vs body mass index with coronary artery disease and cardiovascular events in women. JAMA 292(10):1179-1187, 2004.
• Bakris GL, Gaxiola E, Messerli FH, Mancia G, Erdine S, Cooper-DeHoff R, Pepine CJ, for the INVEST Investigators. Clinical outcomes in the diabetes cohort of the International Verapamil SR-Trandolapril Study. Hypertension 44(5):637-642, 2004.
• Pepine CJ. Editorial: What is the optimal blood pressure and drug therapy for patients with coronary artery disease? JAMA 292(18):2271-2273, 2004.
• Shaw LJ, Merz CN, Pepine CJ, Reis SE, Bittner V, Kip KE, Kelsey SF, Olson M, Johnson BD, Mankad S, Sharaf BL, Rogers WJ, Pohost GM, Sopko G, and the Women’s Ischemia Syndrome Evaluation (WISE) Investigators. The economic burden of angina in women with suspected ischemic heart disease: Results from the National Institutes of Health-National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation. Circulation 114(9):894-904, 2006.
  

Visit Pubmed for full list of publications